Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Martin, Spencer D ^a,b   Brown, Scott D ^a   Wick, Darin A ^a   Nielsen, Julie S ^a   Kroeger, David R ^a   Twumasi Boateng, Kwame ^a   Holt, Robert A ^a,b,c   Nelson, Brad H ^a,b,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEOANTIGEN VACCINE; UNCLASSIFIED DRUG; EPITOPE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BIOINFORMATICS; CANCER CLASSIFICATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; ID8 G7 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MISSENSE MUTATION; MOUSE; MUTATION RATE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; SOMATIC MUTATION; SURVIVAL TIME; TRANSCRIPTOMICS; WHOLE EXOME SEQUENCING; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MUTATION; MUTATION ACCUMULATION; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; FEMALE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; MUTATION; MUTATION ACCUMULATION; OVARIAN NEOPLASMS;

EID: 84971233983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155189     Document Type: Article

References (79)

1. Martin SD, Coukos G, Holt RA, Nelson BH (2015) Targeting the undruggable: Immunotherapy meets personalized oncology in the genomic era. Ann Oncol.
2. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348: 69-74. doi: 10.1126/science.aaa4971 PMID: 25838375
3. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
4. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350: 207-211. doi: 10.1126/science.aad0095 PMID: 26359337
5. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: 2189-2199. doi: 10.1056/NEJMoa1406498 PMID: 25409260
6. Lu YC, Robbins PF (2015) Cancer immunotherapy targeting neoantigens. Semin Immunol.
7. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344: 641-645. doi: 10.1126/science.1251102 PMID: 24812403
8. Heemskerk B, Kvistborg P, Schumacher TN (2013) The cancer antigenome. EMBO J 32: 194-203. doi: 10.1038/emboj.2012.333 PMID: 23258224
9. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. (2014) Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 20: 3401-3410. doi: 10.1158/1078-0432.CCR-14-0433 PMID: 24987109
10. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19: 747-752. doi: 10.1038/nm.3161 PMID: 23644516
11. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. (2014) Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124: 453-462. doi: 10.1182/blood-2014-04-567933 PMID: 24891321
12. Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, et al. (2014) Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 20: 1125-1134. doi: 10.1158/1078-0432.CCR-13-2147 PMID: 24323902
13. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31: e439-442. doi: 10.1200/JCO.2012.47.7521 PMID: 24043743
14. Parker BA, Schwaederle M, Scur MD, Boles SG, Helsten T, Subramanian R, et al. (2015) Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract 11: 442-449. doi: 10.1200/JOP.2015.004127 PMID: 26243651
15. LeBlanc VG, Marra MA (2015) Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us? Cancers (Basel) 7: 1925-1958.
16. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. (2014) Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist 19: 631-636. doi: 10.1634/theoncologist.2013-0405 PMID: 24797821
17. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A (2013) HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 191: 5831-5839. doi: 10.4049/jimmunol.1302101 PMID: 24190657
18. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, et al. (2007) A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 178: 7890-7901. PMID: 17548627
19. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: 495-501. doi: 10.1038/nature12912 PMID: 24390350
20. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218. doi: 10.1038/nature12213 PMID: 23770567
21. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24: 743-750. doi: 10.1101/gr.165985.113 PMID: 24782321
22. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160: 48-61. doi: 10.1016/j.cell.2014.12.033 PMID: 25594174
23. Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, et al. (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125: 3981-3991. doi: 10.1172/JCI82416 PMID: 26389673
24. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. (2015) High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21: 81-85. doi: 10.1038/nm.3773 PMID: 25531942
25. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339: 1546-1558. doi: 10.1126/science.1235122 PMID: 23539594
26. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. (2015) Immunogenicity of somatic mutations in human gastrointestinal cancers. Science.
27. Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, et al. (2014) The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med 12: 55. doi: 10.1186/1479-5876-12-55 PMID: 24565030
28. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, et al. (2005) Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23: 5099-5107. PMID: 15983396
29. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, et al. (2009) Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115: 3924-3934. doi: 10.1002/cncr.24468 PMID: 19536894
30. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72: 1081-1091. doi: 10.1158/0008-5472.CAN-11-3722 PMID: 22237626
31. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692-696. doi: 10.1038/nature14426 PMID: 25901682
32. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515: 577-581. doi: 10.1038/nature13988 PMID: 25428507
33. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572-576. doi: 10.1038/nature14001 PMID: 25428506
34. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15: 668-679. doi: 10.1038/nrc4019 PMID: 26493647
35. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213. PMID: 12529460
36. Zsiros E, Tanyi J, Balint K, Kandalaft LE (2014) Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol 26: 492-500. doi: 10.1097/CCO.0000000000000111 PMID: 25036883
37. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, et al. (2012) A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 61: 373-384. doi: 10.1007/s00262-011-1100-9 PMID: 21927947
38. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, et al. (2009) Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 29: 4779-4784. PMID: 20032435
39. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109: 5797-5802. doi: 10.1073/pnas.1117208109 PMID: 22454499
40. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et al. (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11: 6342-6351. PMID: 16144939
41. Bagnoli M, Canevari S, Figini M, Mezzanzanica D, Raspagliesi F, Tomassetti A, et al. (2003) A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol 88: S140-144. PMID: 12586106
42. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115. PMID: 17062687
43. Cho S, Sun Y, Soisson AP, Dodson MK, Peterson CM, Jarboe EA, et al. (2013) Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model. Anticancer Res 33: 1317-1324. PMID: 23564768
44. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, et al. (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186: 6905-6913. doi: 10.4049/jimmunol.1100274 PMID: 21551365
45. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73: 3591-3603. doi: 10.1158/0008-5472.CAN-12-4100 PMID: 23633484
46. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591. PMID: 10753190
47. Yang T, Wall EM, Milne K, Theiss P, Watson P, Nelson BH (2007) CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res 13: 7172-7180. PMID: 18056198
48. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760. doi: 10.1093/bioinformatics/btp324 PMID: 19451168
49. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079. doi: 10.1093/bioinformatics/btp352 PMID: 19505943
50. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164. doi: 10.1093/nar/gkq603 PMID: 20601685
51. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26. doi: 10.1038/nbt.1754 PMID: 21221095
52. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, et al. (2009) NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61: 1-13. doi: 10.1007/s00251-008-0341-z PMID: 19002680
53. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. PMID: 8287475
54. Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH (2007) Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67: 6442-6450. PMID: 17616705
55. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al. (2009) "MIATA"-minimal information about T cell assays. Immunity 31: 527-528.
56. Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 29: 984-993.
57. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, et al. (2008) SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 105: 3509-3514. doi: 10.1073/pnas.0712269105 PMID: 18303116
58. Kammertoens T, Blankenstein T (2013) It's the peptide-MHC affinity, stupid. Cancer Cell 23: 429-431.
59. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23: 516-526. doi: 10.1016/j.ccr.2013.03.018 PMID: 23597565
60. Obenaus M, Leitao C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, et al. (2015) Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat Biotechnol 33: 402-407. doi: 10.1038/nbt.3147 PMID: 25774714
61. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ (2014) HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2: 522-529. doi: 10.1158/2326-6066.CIR-13-0227 PMID: 24894089
62. van Buuren MM, Calis JJ, Schumacher TN (2014) High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 3: e28836. PMID: 25083320
63. Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, et al. (2014) Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 211: 2231-2248. doi: 10.1084/jem.20141308 PMID: 25245761
64. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404. doi: 10.1038/nature10755 PMID: 22318521
65. Backert L, Kohlbacher O (2015) Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 7: 119. doi: 10.1186/s13073-015-0245-0 PMID: 26589500
66. Gowthaman U, Agrewala JN (2008) In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J Proteome Res 7: 154-163. PMID: 18034454
67. Singh SP, Mishra BN (2015) Major histocompatibility complex linked databases and prediction tools for designing vaccines. Hum Immunol.
68. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. PMID: 15032581
69. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science.
70. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. (2015) Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol.
71. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339. doi: 10.1038/nature12634 PMID: 24132290
72. Chui MH, Gilks CB, Cooper K, Clarke BA (2013) Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol 20: 378-386. doi: 10.1097/PAP.0b013e3182a92cf8 PMID: 24113308
73. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. (2013) Signatures of mutational processes in human cancer. Nature 500: 415-421. doi: 10.1038/nature12477 PMID: 23945592
74. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget.
75. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: 1127-1133. doi: 10.1038/ng.2762 PMID: 24071851
76. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521: 489-494. doi: 10.1038/nature14410 PMID: 26017449
77. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101: 2290-2296. PMID: 9593785
78. Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, et al. (1998) Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 188: 1005-1016. PMID: 9743519
79. Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A, et al. (2007) Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110: 1055-1063. PMID: 17409267